RougeTx

Raised $58M in a Series A round, announced 6 October 2026.

Round

RougeTx raised $58M in Series A funding.

Amount: $58M
Stage: Series A
Announced: 6 October 2026
Leads: BioGeneration Ventures, Angelini Ventures, Kurma Partners
Other investors: Aurea, Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, Kerna Ventures
Use of funds: Financing will advance RTX-001, RougeTx's lead program, toward first-in-human clinical development for hereditary hemorrhagic telangiectasia.
Checked: Amount and date checked against the press source

Develops first-in-class disease-modifying therapies restoring vascular integrity by targeting pericyte dysfunction.

MediaBoost gets your round in front of the press, future hires and your next investors.